Table 1.
Patient characteristics according to treatment arm
| 600 mg bid day 1–21 (n=80) | 600 mg bid d 1–7, 15–21 (n=85) | 300 mg bid day 1–21 (n=82) | 300 mg bid d 1–7, 15–21 (n=84) | ||
|---|---|---|---|---|---|
| Age (years) | |||||
| Median | 78 | 78 | 78 | 78 | |
| Range | 70–91 | 70–94 | 70–92 | 70–91 | |
| Gender | |||||
| Male | 68% | 58% | 72% | 64% | |
| AML onset | |||||
| De novo | 50% | 49% | 48% | 52% | |
| MDS | 50% | 44% | 46% | 43% | |
| Therapy | 0% | 7% | 6% | 5% | |
| Zubrod PS | |||||
| 0 | 25% | 27% | 28% | 23% | |
| 1 | 58% | 45% | 47% | 50% | |
| WBC, median | 2.9 | 2.9 | 2.4 | 4.7 | |
| HGB, median | 9.3 | 9.5 | 9.5 | 9.5 | |
| PLT, median | 66 | 44 | 61 | 45 | |
| Marrow blasts (%)1 | 44 | 40 | 45 | 40 | |
| Peripheral blasts (%) | 11 | 9 | 4 | 17 |